Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX:HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that on March 16, 2019, Amarin...
From a single drop of blood from the tip of a finger, the point-of-care technology generates white blood cell counts and neutrophils numbers in minutes When approved in Canada, the Athelas One...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it will release its...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a specialty pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Greg Gubitz, the...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, is pleased to announce that it...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system and cardiovascular markets, announces that it has received...
REDUCE-IT™ cardiovascular outcomes study of Vascepa®, for which HLS has in-licensed exclusive Canadian rights, exceeded primary endpoint demonstrating an approximately 25% relative risk...
Cardiovascular Death Reduced by 20% Fatal or Nonfatal Heart Attacks Reduced by 31% Fatal or Nonfatal Stroke Reduced by 28% Urgent or Emergent Coronary Revascularization Reduced by 35%...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will release its third quarter...
REDUCE-IT is First Outcomes Study to Assess Treatment of Patients with LDL-C Controlled by Statin Therapy, Persistent Elevated Triglycerides and Other Cardiovascular Risk Factors Results Specific...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular markets, announces that it has...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in central nervous system ("CNS") and cardiovascular markets, announces that it has...
Revenue of $16.3 million, Net Loss of $0.6 million and Adjusted EBITDA of $11.0 million, which were all in line with expectations Debt refinancing co-led by JPMorgan Chase Bank, N.A. and Silicon...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will release its second quarter...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces voting results for the election of directors at its Annual Meeting of Shareholders held on June 22, 2018 in Toronto, Ontario. A...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces details of its upcoming Annual Meeting of Shareholders. Date: Friday June 22, 2018 Time: 10:00 a.m. ET Location: Blake, Cassels...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that it has entered into an automatic share purchase plan (the "ASPP") with a designated broker in order to facilitate...
Commenced trading on the TSX Venture Exchange (Toronto Stock Exchange) Revenue of $13.2M in Q1 2018 vs $15.6M in Q1 2017. Clozaril generates year-over-year growth; Absorica royalties reflect...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that the TSX Venture Exchange ("TSXV") has approved the Company's Notice of Intention to Make a Normal Course Issuer Bid...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that it will release its first quarter...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), a specialty pharmaceutical company specializing in CNS and Cardiovascular markets, announces that Mr. Ryan C. Lennox has been named...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSXV: HLS) announces that it intends to redeem 9,321,492 (71.83%) of the Company's outstanding Class A preferred shares ("Preferred Shares") on May...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX-V: HLS), an emerging specialty pharmaceutical company, announces that Greg Gubitz, CEO, will present at the Bloom Burton & Co. Healthcare...
Revenue was $75.1 million, a 39% increase year-over-year Cash generated from operations was $27.2 million, a 25% increase year-over-year Reverse Take-Over and listing on TSX-V completed post year end
HLS Therapeutics Inc. (TSXV: HLS) today announced that it will release its fourth quarter 2017 financial results by press release on Thursday, March 29, 2018, prior to market open. The Company...